Journal
JOURNAL OF CLINICAL GASTROENTEROLOGY
Volume 47, Issue 3, Pages 212-221Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MCG.0b013e3182732ff5
Keywords
inflammatory bowel disease; Crohn's disease; ulcerative colitis; mucosal healing; endoscopic; histologic
Categories
Funding
- UCB
Ask authors/readers for more resources
It is becoming increasingly recognized that purely clinical endpoints may not be sufficient in the treatment of patients with inflammatory bowel disease. As such, mucosal disease assessment has become a prominent component of the majority of recent clinical trials in Crohn's disease and ulcerative colitis. There is mounting evidence that the attainment of mucosal healing leads to improved clinical outcomes in both Crohn's disease and ulcerative colitis. However, the use of mucosal healing as a therapeutic endpoint in inflammatory bowel disease is in its early stages, as a number of issues limit its application to routine clinical practice.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available